[CLDN] Celladon Corporation

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization: 27.54 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.15 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart CLDN

Refresh chart

Description: Celladon Corporation, a clinical-stage biotechnology company, focuses on developing treatments for heart failure, diabetes, and neurodegenerative diseases. The company?s lead product candidate includes MYDICAR that uses genetic enzyme replacement therapy to correct the Sarco/endoplasmic reticulum Ca 2+ -ATPase 2a enzyme deficiency in heart failure patients that results in inadequate pumping of the heart. Its MYDICAR product is developed to treat patients with systolic heart failure, diastolic heart failure, and advanced heart failure, as well as to treat pulmonary arterial hypertension and arteriovenous fistula maturation failure. The company was founded in 2000 and is headquartered in San Diego, California.

Fundamental Ratios
Shares Outstanding23.95 M EPS-1.94 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-0.59
P/E To EPS Growth P/S P/BV0.47 Price/Cash Per Share0.39
Price/Free Cash Flow-0.92 ROA-59.31% ROE-74.76% ROI
Current Ratio11.78 Quick Ratio Long Term Debt/Equity Debt Ratio0.11
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities640 K Cash From Investing Activities49.71 M Cash From Operating Activities-14.77 M Gross Profit
Net Profit-16.75 M Operating Profit-16.3 M Total Assets73.24 M Total Current Assets72.26 M
Total Current Liabilities6.13 M Total Debt10.38 M Total Liabilities15.13 M Total Revenue
Technical Data
High 52 week27.26 Low 52 week0.89 Last close1.15 Last change-1.71%
RSI68.89 Average true range0.08 Beta1.09 Volume
Simple moving average 20 days9.71% Simple moving average 50 days6.9% Simple moving average 200 days-8.57%
Performance Data
Performance Week3.6% Performance Month25% Performance Quart-24.84% Performance Half-4.17%
Performance Year-95.56% Performance Year-to-date-21.77% Volatility daily3.38% Volatility weekly7.57%
Volatility monthly15.51% Volatility yearly53.72% Relative Volume0% Average Volume165.28 K
New High New Low

News

2016-02-29 08:00:00 | Eiger to Participate in Cowen & Company 2016 Health Care Conference

2015-12-08 13:17:39 | CELLADON CORP Financials

2015-11-21 10:25:52 | 6 BioHealth Movers That Now Cannot Be Ignored

2015-11-19 17:36:00 | INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Celladon Corporation of Commencement of an Investigation In Connection With the Fairness of the Sale of the Company to Eiger BioPharmaceuticals, Inc. - CLDN

2015-11-19 10:15:00 | Celladon CLDN Stock Popping on Eiger Merger

2015-11-19 09:45:00 | CELLADON ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Launches an Investigation into the Proposed Merger of Celladon Corporation; Are Celladon Shareholders Getting a Fair Deal?

2015-09-10 11:00:00 | Spark Tries to Quell Investor Fears About Gene Therapy Test

2015-06-26 10:40:38 | Can Celladon Weather the Storm?

2015-06-19 15:36:10 | Mangrove Partners Finds New Stocks Selling At Bargain Prices

2015-06-01 10:50:07 | Can Celladon Turn Itself Around With Its New Plan?

2015-04-27 17:01:49 | US STOCKS-Wall St ends down as biotechs drop 4 pct; Apple up late

2015-04-27 16:48:59 | DuPont and Mylan are big market movers

2015-04-27 16:38:53 | US STOCKS-Wall St ends down as biotechs drop 4 pct

2015-04-27 16:04:03 | The 52-Week Low Club for Monday

2015-04-27 14:50:49 | US STOCKS-Wall St slips as biotechs drop; Apple shares up

2015-04-27 11:37:51 | US STOCKS-Wall St edges higher ahead of Apple results, S&P hits record

2015-04-27 10:55:06 | A Real Heartbreak for Celladon

2015-04-27 09:09:08 | US STOCKS-Wall St to open up ahead of Apple earnings, Fed meeting later this week

2015-04-27 09:00:01 | Top Analyst Upgrades and Downgrades: Apple, Celladon, Newmont, 3D Systems, Twitter, Disney and More

2015-04-26 17:44:37 | Celladon says heart treatment fails in trial

2015-04-01 11:20:01 | Biotechs Raising New Capital in Droves

2015-03-31 10:01:24 | Celladon reports 4Q loss